ReNerve

ReNerve Current Ratio

The Current Ratio of ReNerve (RNV.AX) as of Nov 16, 2026 is 1.55. In the previous year, Current Ratio was 1.25 — a change of 23.74% (higher).

Current Ratio

1.55

YoY

23.74%

Last updated:

Current Ratio of ReNerve is 2026 1.55 . Current Ratio of ReNerve was 2025 1.25 . It decreases by 23.74% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd develops medical devices for nerve repair and soft tissue surgery, focusing on products that accelerate regeneration and prevent scarring. The company offers NervAlign Nerve Cuff, a protective wrap for repaired nerves, and NervAlign Nerve Graft, which allows surgeons to repair damaged nerves without harvesting the sural nerve. NervAlign Bionic Nerve combines polymer technology with nerve grafts to create a replacement nerve using shaped ionic polymers for distal nerve stimulation. These products target surgical procedures requiring nerve repair, with hospitals and surgical centers as primary buyers. The company's revenue comes from selling NervAlign products directly to healthcare providers involved in nerve repair surgeries. NervAlign Nerve Cuff is designed for protecting repaired nerves during surgery, while NervAlign Nerve Graft eliminates the need for patient nerve harvesting. NervAlign Bionic Nerve represents a future product line aiming to provide advanced nerve replacement solutions. The target market includes surgical teams specializing in peripheral nerve procedures and medical facilities equipped for complex soft tissue surgeries. ReNerve Ltd's products are positioned for use in peripheral nerve repair and related soft tissue surgical procedures. The NervAlign Nerve Cuff protects injured nerves during surgical repair, the NervAlign Nerve Graft enables nerve repair without patient nerve harvesting, and NervAlign Bionic Nerve aims to stimulate distal nerve ends using ionic polymers. These products are sold to hospitals and surgical centers that perform nerve repair surgeries, with the company focusing on accelerating tissue regeneration and reducing complications. ReNerve is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReNerve stock

Current Ratio of ReNerve is 1.55 in 2026.

Current Ratio of ReNerve changed from 1.25 to 1.55, representing a 23.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio ReNerve since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's ReNerve with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ReNerve

All Key Metrics — ReNerve